- Galectin Therapeutics (GALT) announced on Tuesday it has reached an agreement with the FDA regarding a Phase 3 program to test its lead asset belapectin in cirrhosis and portal hypertension linked to the liver disease metabolic dysfunction-associated steatohepatitis (MASH).
- In